Interesting to compare how Novartis put such a positive spin on the PARAGON-HF trial of Entresto despite missing statistical significance for CHF with how the BETonMACE CHF results have been reported. 
https://www.novartis.com/news/media-releases/novartis-paragon-hf-trial-suggests-entresto-benefit-hfpef-patients-narrowly-misses-primary-endpoint
PARAGON-HF "narowly missed primary endpoint" for CHF and results "suggested clinically important benefit" but BETonMACE "failed" and we've heard no more on the CHF results despite a significant reduction in CHF in the total participants!!